Therapeutic drug monitoring of phenytoin in critically ill patients

Pharmacotherapy

Volumn 28, Issue 11 PART 1, 2008, Pages 1391-1400

  Von Winckelmann, Sandrina L ^a   Spriet, Isabel ^a   Willems, Ludo ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Critically ill patients; Free drug monitoring; Hypoalbuminemia; Phenytoin; Therapeutic drug monitoring

Indexed keywords

AMIODARONE; ATORVASTATIN; CARBAMAZEPINE; CLONAZEPAM; CYCLOSPORIN; DEXAMETHASONE; DIAZEPAM; DICOUMAROL; DIGOXIN; DISOPYRAMIDE; ETHOSUXIMIDE; FELBAMATE; ITRACONAZOLE; KETOCONAZOLE; LAMOTRIGINE; LEVOTHYROXINE; METRONIDAZOLE; MEXILETINE; MIDAZOLAM; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; SIMVASTATIN; TACROLIMUS; THEOPHYLLINE; TIAGABINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VORICONAZOLE;

ATAXIA; BINDING AFFINITY; BINDING SITE; BLOOD SAMPLING; CHROMATOGRAPHY; CRITICALLY ILL PATIENT; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG METABOLISM; DRUG MONITORING; DRUG OXIDATION; DRUG PROTEIN BINDING; ENTEROPATHY; EPILEPSY; GENE EXPRESSION; GENETIC POLYMORPHISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPOALBUMINEMIA; IMMUNOASSAY; KIDNEY DISEASE; KIDNEY FAILURE; LIVER DISEASE; MALNUTRITION; NEUROLOGIC DISEASE; NYSTAGMUS; PREGNANCY; REVIEW; SEIZURE; SEPSIS; TRAUMATIC BRAIN INJURY; ULTRAFILTRATION; VISUAL DISORDER;

ANIMALS; ANTICONVULSANTS; CRITICAL ILLNESS; DRUG MONITORING; HUMANS; PHENYTOIN;

EID: 55549136045     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.28.11.1391     Document Type: Review

References (80)

1. Richens A. Clinical pharmacokinetics of phenytoin. Clin Pharmacokinet 1979;4:153-69.
2. Joerger M, Huitema AD, Boogerd W, van der Sande JJ, Schellens JH, Beijnen JH. Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients. Basic Clin Pharmacol Toxicol 2006;99:133-40.
3. Winter ME, ed. Phenytoin. In: Basic clinical pharmacokinetics, 3rd ed. Vancouver, WA: Applied Therapeutics, 1994:312-48.
4. Lindow J, Wijdicks E. Phenytoin toxicity associated with hypoalbuminemia in critically ill patients. Chest 1994;105:602-4.
5. De Schoenmakere G, De Waele J, Terryn W, et al. Phenytoin intoxication in critically ill patients. Am J Kidney Dis 2004;45:189-92.
6. Kemper EM, van Kan HJ, Speelman P, de Gans K, Beijnen JH, Schellens JH. Severe phenytoin intoxication in patients with hypoalbuminemia. Ned Tijdschr Geneeskd 2007;151:138-41.
7. Thakral A, Shenoy R, Deleu D. Acute visual dysfunction following phenytoin-induced toxicity. Acta Neurol Belg 2003;103:218-20.
8. Neels HM, Sierens AC, Naelaerts K, Scharpé SL, Hatfield GM, Lambert WE. Therapeutic drug monitoring of old and newer anti-epileptic drugs. Clin Chem Lab Med 2004;42(11):1228-55.
9. Brostoff JM, Birns J, McCrea D. Phenytoin toxicity: an easily missed cause of cerebellar syndrome. J Clin Pharm Ther 2008;33:211-14.
10. Grandison MK, Boudinot FD. Age-related changes in protein binding of drugs. Clin Pharmacokinet 2000;38(3):271-90.
11. Dasgupta A. Usefulness of monitoring free (unbound) concentrations of therapeutic drugs in patient management. Clin Chim Acta 2007;377(1-2):1-13.
12. Burt M, Anderson DC, Kloss J, Apple FS. Evidence-based implementation of free phenytoin therapeutic drug monitoring. Clin Chem 2000 46(8):1132-5.
13. Rambeck B, Schnabel R, May T, Jürgens U, Villagrán R. Postmortem serum protein binding and brain concentrations of antiepileptic drugs in autoptic specimens from 45 epileptic patients. Ther Drug Monit 1990;12(6):533-40.
14. Stowe CD, Lee KR, Storgion SA, Phelps SJ. Altered phenytoin pharmacokinetics in children with severe, acute traumatic brain injury. J Clin Pharmacol 2000;40:1452-61.
15. Shohrati M, Rouini MR, Mojtahedzadeh M, Firouzabadi M. Evaluation of phenytoin pharmacokinetics in neurotrauma patients. DARU 2007;15(1):34-40.
16. McKindley DS, Bradley BA, Hess MM, Rodman JH, Feler C, Fabian TC. Effect of acute phase response on phenytoin metabolism in neurotrauma patients. J Clin Pharmacol 1997;37:129-39.
17. McNamara JO. Drugs effective in the therapy of the epilepsies. In: Hardman JG, Limbird LE, Goodman GA, eds. Goodman and Gilman's the pharmacological basis of therapeutics, 10th ed. New York: McGraw-Hill, 2001:528-31.
18. Ashley C, Currie A, eds. Phenytoin. In: The renal drug handbook. Oxon, United Kingdom: Radcliffe Medical, 2004:416-17.
19. Power BM, Forbes AM, Vernon van Heerden PV, Ilett KF. Pharmacokinetics of drugs used in critically ill adults. Clin Pharmacokinet 1998;34(1):25-56.
20. Park GR. Pharmacokinetics and pharmacodynamics in the critically ill patient. Xenobiotica 1993;23(11):1195-230.
21. Patsalos PN, Fröscher W, Pisani F, van Rijn CM. The importance of drug interactions in epilepsy therapy. Epilepsia 2002;43(4):365-85.
22. Perucca E. Clinical relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 2006;61(3):246-55.
23. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol 2003;2:347-56.
24. Au Yeung SC, Ensom MH. Phenytoin and enteral feedings: does evidence support an interaction. Ann Pharmacother 2000;34(7-8):896-905.
25. Baxter K, ed. Anticonvulsants. In: Stockley's drug interactions, 7th ed. London, United Kingdom: Pharmaceutical Press, 2006:373-4.
26. Kitchen D, Smith D. Problems with phenytoin administration in neurology/neurosurgery ITU patients receiving enteral feeding. Seizure 2001;10(4):265-8.
27. Randall CTC, Tett SE. Phenytoin pharmacokinetics after intravenous administration to patients receiving enteral tube feeding. Pharm World Sci 1994;16(5):217-24.
28. Dasgupta A. Clinical utility of free drug monitoring. Clin Chem Lab Med 2002;40(10):986-93.
29. Dasgupta A, McLemore JL. Elevated free phenytoin and free valproic acid concentrations in sera of patients infected with human immunodeficiency virus. Ther Drug Monit 1998;20(1):63-7.
30. Perucca E, Ruprah M, Richens A. Altered drug binding to serum proteins in pregnant women: therapeutic relevance. J R Soc Med 1981;74(6):422-6.
31. Barré J, Didey F, Deloin F, Tillement JP. Problems in therapeutic drug monitoring: free drug level monitoring. Ther Drug Monit 1988;10(2):133-43.
32. Zielmann S, Mielck F, Kahl R, et al. A rational basis for the measurement of free phenytoin concentrations in critically ill trauma patients. Ther Drug Monit 1994;16:139-44.
33. Mehvar R. Role of protein binding in pharmacokinetics. Am J Pharm Educ 2005;69(5):1-8.
34. Monaghan MS, Marx MA, Olsen KM, Turner PD, Bergman KL. Correlation and prediction of phenytoin protein binding using standard laboratory parameters in patients after renal transplantation. Ther Drug Monit 2001;23(3):263-7.
35. Bailey DN, Briggs JR. The binding of selected therapeutic drugs to human serum alpha-1 acid glycoprotein and to human serum albumin in vitro. Ther Drug Monit 2004;26(1):40-3.
36. Dasgupta A, Timmerman TG. In vitro displacement of phenytoin from protein binding by nonsteroidal antiinflammatory drugs tolmetin, ibuprofen, and naproxen in normal and uremic sera. Ther Drug Monit 1196;18(1):97-9.
37. Benet LZ, Hoener B. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 2002;71:115-21.
38. Rolan PE. Plasma protein binding displacement interactions: why are they still regarded as clinically important? Br J Clin Pharmacol 1994;37:125-8.
39. Ensom MH. Comment: unbound drug concentration versus unbound drug fraction. Ann Pharmacother 2002;36(4):731-2, authors' reply 732.
40. Iwamoto T, Kagawa Y, Naito Y, Kuzuhara S, Okuda M. Clinical evaluation of plasma free phenytoin measurement and factors influencing its protein binding. Biopharm Drug Dispos 2006;27:77-84.
41. Aarons L, Ahmed IA, Deleu D. Estimation of population pharmacokinetic parameters of free phenytoin in adult epileptic patients. Arch Med Res 2005;36:49-53.
42. Hung CC, Lin CJ, Chen CC, Chang CJ, Liou HH. Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms. Ther Drug Monit 2004;26(5):534-40.
43. Anderson GD. Pharmacokinetic, pharmacodynamic and pharmacogenetic targeted therapy of antiepileptic drugs. Ther Drug Monit 2008;30(2):173-80.
44. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol 2003;2:473-81.
45. van Breemen MSM, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol 2007;6:421-30.
46. Michelucci R. Optimizing therapy of seizures in neurosurgery. Neurology 2006;67(suppl 4):S14-18.
47. Manoranjenni C, Miller R, Seymour M. Phenytoin autoinduction. Ther Drug Monit 1998;20(1):60-2.
48. Kilpatrick CJ, Wanwimolruk S, Wing LM. Plasma concentrations of unbound phenytoin in the management of epilepsy. Br J Clin Pharmacol 1984;17:539-46.
49. Peterson GM, Khoo BH, von Witt RJ. Clinical response in epilepsy in relation to total and free serum levels of phenytoin. Ther Drug Monit 1991;13(5):415-19.
50. Maurer TS, DeBartolo DB, Tess DA, Scott DO. Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice. Drug Metab Dispos 2005;33(1):175-81.
51. Yeh JS, Shir JS, Green AL, Bodiwala D, Brydon HL. Changes in plasma phenytoin level following craniotomy. Br J Neurosurg 2006;20(6):403-6.
52. Löscher W, Potschka H. Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J Pharmacol Exp Ther 2002;301(1):7-14.
53. Banh HL, Burton ME, Sperling MR. Interpatient and intrapatient variability in phenytoin protein binding. Ther Drug Monit 2002;24(3):379-85.
54. Booker HE, Darcey B. Serum concentrations of free diphenylhydantoin and their relationship to clinical intoxication. Epilepsia 1973;2:177-84.
55. Lenn NJ, Robertson M. Clinical utility of unbound antiepileptic drug blood levels in the management of epilepsy. Neurology 1992;42:988-90.
56. Bertucci C, Domenici E. Reversible and covalent binding of drugs to human serum albumin: methodological approaches and physiological relevance. Curr Med Chem 2002;9(15):1463-81.
57. Barré J, Chamouard JM, Houin G, Tillement JP. Equilibrium dialysis, ultrafiltration, and ultracentrifugation compared for determining the plasma-protein-binding characteristics of valproic acid. Clin Chem 1985;31(1):60-4.
58. Pacifici GM, Viani A. Methods of determining plasma and tissue binding of drugs: pharmacokinetic consequences. Clin Pharmacokinet 1992;23(6):449-68.
59. Wright JD, Boudinot FD, Ujhelyi MR. Measurement and analysis of unbound drug concentrations. Clin Pharmacokinet 1996;30(6):445-62.
60. Soldin SJ. Free drug measurements. When and why? An overview. Arch Pathol Lab Med 1999;123(9):822-3.
61. Liu H, Delgado MR. Therapeutic drug concentration monitoring using saliva samples: focus on anticonvulsants. Clin Pharmacokinet 1999;36(6):453-70.
62. Drobitch RK, Svensson CK. Therapeutic drug monitoring in saliva: an update. Clin Pharmacokinet 1992;23:365-79.
63. al Za'abi M, Deleu D, Batchelor C. Salivary free concentrations of anti-epileptic drugs: an evaluation in a routine clinical setting. Acta Neurol Belg 2003;103:19-23.
64. Dager WE, Inciardi JF, Howe TL. Estimating phenytoin concentrations by the Sheiner-Tozer method in adults with pronounced hypoalbuminemia. Ann Pharmacother 1995;29(7-8):667-70.
65. Mlynarek ME, Peterson EL, Zarowitz BJ. Predicting unbound phenytoin concentrations in the critically ill neurosurgical patient. Ann Pharmacother 1996;30(3):219-23.
66. Mauro LS, Mauro VF, Bachmann KA, Higgins JT. Accuracy of two equations in determining normalized phenytoin concentrations. DICP 1989;23:64-8.
67. Beck DE, Farringer JA, Ravis WR, Robinson CA. Accuracy of three methods for predicting concentrations of free phenytoin. Clin Pharm 1987;6(11):888-94.
68. Kodama H, Kodama Y, Itokazu N, Shinozawa S, Kanemaru R, Sugimoto T. Effect of temperature on serum protein binding characteristics of phenytoin in monotherapy paediatric patients with epilepsy. J Clin Pharm Ther 2001;26:175-9.
69. Wolf G, McClain C, Zurakowski D, Dodson B, McManus ML. Total phenytoin concentrations do not accurately predict free phenytoin concentrations in critically ill children. Pediatr Crit Care Med 2006;7(5):1-6.
70. Mamiya K, Yukawa E, Matsumoto T, Aita C, Goto S. Synergistic effect of valproate coadministration and hypoalbuminemia on the serum-free phenytoin concentration in patients with severe motor and intellectual disabilities. Clin Neuropharmacol 2002;25(4):230-3.
71. Haidukewych D, Rodin EA, Zielinskli JJ. Derivation and evaluation of an equation for prediction of free phenytoin concentration in patients with valproic acid. Ther Drug Monit 1989;11(2):134-9.
72. Kerrick JM, Wolff DL, Graves NM. Predicting unbound phenytoin concentrations in patients receiving valproic acid: a comparison of two prediction methods. Ann Pharmacother 1995;29(5):470-4.
73. May TW, Rambeck B, Nothbaum N. Nomogram for the prediction of unbound phenytoin concentrations in patients on a combined treatment of phenytoin and valproic acid. Eur Neurol 1991;31(1):57-60.
74. Eadie MJ. Therapeutic drug monitoring: antiepileptic drugs. Br J Clin Pharmacol 2001;52:11S-20.
75. Warner A, Privitera M, Bates D. Standards of laboratory practice: antiepileptic drug monitoring. Clin Chem 1998;44(5):1085-95.
76. Lagneau F, Perbet S, Delefosse D, Wernet A, Marty J. Drugs pharmacokinetics in ICU patients: consequences of hypoalbuminemia upon drugs monitoring and dosing scheme [letter]. Intensive Care Med 2004;30:1247.
77. Rimmer EM, Buss DC, Routledge PA, Richens A. Should we routinely measure free plasma phenytoin concentration? Br J Clin Pharmacol 1984;17:99-102.
78. De Santis A, Villani R, Sinisi M, Stocchetti N, Perucca E. Add-on phenytoin fails to prevent early seizures after surgery for supratentorial brain tumors: a randomized controlled study. Epilepsia 2002;43(2):175-82.
79. Young B, Rapp RP, Norton JA, Haack D, Tibbs PA, Bean JR. Failure of prophylactically administered phenytoin to prevent late posttraumatic seizures. J Neurosurg 1983;58(2):236-41.
80. Temkin NR, Dikmen SS, Wilensky AJ, Keihm J, Chabal S, Winn HR. A randomized, double-blind study of phenytoin for the prevention of post-traumatic seizures. N Engl J Med 1990;323(8):497-502.